Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Journal Article
·
· New England Journal of Medicine
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- USDOE Office of Science (SC)
- OSTI ID:
- 1405016
- Journal Information:
- New England Journal of Medicine, Vol. 374, Issue 1; ISSN 0028-4793
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Journal Article
·
Fri Jun 29 00:00:00 EDT 2012
· Biochemical and Biophysical Research Communications
·
OSTI ID:1405016
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Journal Article
·
Mon Mar 02 00:00:00 EST 2015
· Proceedings of the National Academy of Sciences of the United States of America
·
OSTI ID:1405016
+20 more
Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Journal Article
·
Thu Jun 12 00:00:00 EDT 2014
· Journal of Medicinal Chemistry
·
OSTI ID:1405016
+30 more